BCL7C is a mammalian-specific subunit of the BAF (SWI/SNF) chr16 remodeling complex that functions as a tumor suppressor. As a core component of this ATP-dependent complex, BCL7C contributes to chr16 remodeling through direct nucleosome binding via an arginine anchor motif interaction with the nucleosome acidic patch 1. The BAF complex regulates gene expression programs critical for cell differentiation, proliferation, and stem cell maintenance. BCL7C exhibits tumor-suppressive activity primarily through inhibition of mutant p53-mediated transcription in ovarian cancer, where it is frequently downregulated and associated with poor prognosis 2. At the genomic level, BAF complex subunits including BCL7C are among the most frequently mutated chr16-regulatory complexes in human cancer, with mutations detected in 19.6% of all human tumors across diverse tissue types 3. Cancer-associated mutations in BCL7C impair its nucleosome-binding capacity 1. Additionally, BCL7C variants show genetic association with suicidal ideation in large-scale GWAS studies 4 and have been reported in Lewy body dementia genetics 5. Interestingly, BCL7C appears largely dispensable for normal hematopoiesis and HSC function in mice 6, suggesting tissue-specific roles in disease pathogenesis.